In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
about
A review of in-vivo optical properties of human tissues and its impact on PDTA method for determination of the absorption and scattering properties interstitially in turbid media.Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy.High-field magnetic resonance imaging of the response of human prostate cancer to Pc 4-based photodynamic therapy in an animal modelPhotodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.Reconstruction of optical properties using a diffusion model for interstitial diffuse optical tomography.Pre-clinic study of uniformity of light blanket for intraoperative photodynamic therapyCharacterization of tissue optical properties for prostate PDT using interstitial diffuse optical tomography.A fast heterogeneous algorithm for light fluence rate for prostate photodynamic therapy.Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm.Prostate PDT dosimetry.Optimization of light source parameters in the photodynamic therapy of heterogeneous prostate.Determination of in vivo light fluence distribution in a heterogeneous prostate during photodynamic therapy.Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapyOptical properties of human prostate at 732 nm measured in mediated photodynamic therapyInterstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.In-vivo light dosimetry of interstitial PDT of human prostateOptimization of light sources for prostate photodynamic therapyTargeting Photochemical Scalpels or Lancets in the Photodynamic Therapy Field-The Photochemist's Role.Photodynamic therapy for treatment of solid tumors--potential and technical challenges.Feasibility of interstitial diffuse optical tomography using cylindrical diffusing fibers for prostate PDTOn the in vivo photochemical rate parameters for PDT reactive oxygen species modeling.Photosensitizers in prostate cancer therapy.The inhibitory effect of photodynamic therapy and of an anti-VCAM-1 monoclonal antibody on the in vivo growth of C6 glioma xenografts.Determination of optical properties in heterogeneous turbid media using a cylindrical diffusing fiber.Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiationTreatment planning using tailored and standard cylindrical light diffusers for photodynamic therapy of the prostate.
P2860
Q26992342-176F02AC-CB01-4E74-8DBC-1928C63651B6Q31170393-582C8A42-B22B-4097-895D-D22E5F9E6CE1Q33215056-18B184E0-5140-421D-8BC8-E8250AD713D3Q33303889-467A223E-7565-4F3C-8AD9-2C36FC1ABADCQ34068220-AC231980-7F6D-485F-A0F7-53873E221D7AQ35604066-CB1ADB89-60A8-4E4D-B3CC-A424DEC4693BQ35619282-7C9BEA6A-613D-49FC-8910-9E8F6CCE1AF9Q35624591-D309A5AA-6810-49C6-A2F7-DAD74F3B3467Q35627746-9561DEE6-D3AD-4C12-87FF-8F197B2DE9FEQ35743660-D1F18075-1797-4877-A74C-44088E04D07AQ35748396-895A675E-DB68-4154-A6B5-99C597B7248EQ35749013-CD77231E-BE08-43DE-B948-2D60088A8767Q35749017-FC940A67-0620-4B06-9BA6-5236F5161BF3Q35751211-16E077DE-1999-4E41-9450-3AD601D94428Q35761155-512FE20A-993A-4389-83A0-E6DF70E620F0Q35763223-FAC570C7-77F8-4977-9E18-F7D045BC09D3Q35771754-08E16D7A-F341-4AAC-9FE3-242B96F7CF2AQ35795362-337FAD6D-66F9-4B7F-B9EC-644C68132B8FQ36333587-8A403441-5B55-4B6A-A40F-3E8281D3E665Q36995497-155F1026-17C8-460C-ADEB-0C7B7187E07EQ37137313-70B84CE7-7611-4F54-B262-6E854AC78D7CQ38976558-B02E03D7-804E-405F-A64E-4C06FB6F77C3Q39254736-78E6F5E5-4335-4B39-85E1-EAB18B71FD04Q39553122-34B5A6C8-08E4-40DE-AAA6-98C7D5BFD3C9Q41897647-C33AEC7E-5864-438F-B361-E1636D6C6274Q42542248-44E1EC3E-E470-4CB4-A50C-32F3207859ADQ43170864-0CF6D180-45BC-4E63-8FE7-22DA5BFF85D7
P2860
In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
In vivo optical properties of ...... mediated photodynamic therapy.
@en
type
label
In vivo optical properties of ...... mediated photodynamic therapy.
@en
prefLabel
In vivo optical properties of ...... mediated photodynamic therapy.
@en
P2093
P1476
In vivo optical properties of ...... -mediated photodynamic therapy
@en
P2093
Amy S Kapatkin
Andreea Dimofte
Carmen E Rodriguez
Eli Glatstein
R Alex Hsi
Stephen M Hahn
Teodor G Vulcan
P356
10.1562/0031-8655(2003)077<0081:IVOPON>2.0.CO;2
P577
2003-01-01T00:00:00Z